Trimel to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, ONTARIO--(Marketwired - Jun 16, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the 2014 Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18th, 2014 at 2:30 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.

Trimel Pharmaceuticals CorporationKenneth HowlingChief Financial Officer(416) 679-0536ir@trimelpharmaceuticals.comwww.trimelpharmaceuticals.com

Trilogy International Pa... (TSX:TRL)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Trilogy International Pa....
Trilogy International Pa... (TSX:TRL)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Trilogy International Pa....